Search results

Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

Result type

Technology appraisal guidance

Published

23 January 2013

Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.

Result type

Technology appraisal guidance

Published

13 June 2018

Topic prioritisation

Result type

Interventional procedures guidance

Status

Topic prioritisation

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

Result type

HealthTech guidance

Published

26 February 2014

This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.

Result type

NICE guideline

Last updated

6 June 2018

Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

Result type

HealthTech guidance

Published

25 August 2004

NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib. This is because Lilly did not provide an evidence submission.

Result type

Technology appraisal guidance

Published

30 October 2019

NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.

Result type

Technology appraisal guidance

Published

20 April 2022

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

Awaiting development

Evidence-based recommendations on radiofrequency ablation of hepatocellular carcinoma. This involves using heat to destroy the part of the liver that contains the cancer.

Result type

HealthTech guidance

Published

23 July 2003